Ga direct naar de inhoud

Ga direct naar de navigatie

Uitgave van

Berichten met het trefwoord ‘Bristol-Myers Squibb’

Lung cancer doctors eye Merck’s Keytruda over Bristol’s Opdivo

Recent clinical trial results are likely to lead doctors to treat more patients who have a common form of lung cancer with a Merck drug at the expense of a Bristol-Myers Squibb medication at least until more data emerges, oncologists and analysts say.

Bron: Reuters Meer lezen »

Bristol-Myers Squibb grows revenues 17% to $4.9 billion in Q2 2016

Bristol-Myers Squibb has announced its financial results for the second quarter of 2016, noting sizeable year-on-year sales growth and leaps forward in key regulatory and clinical aspects of its Immuno-oncology pipeline.  

Bron: InPharm.com Meer lezen »

Bristol-Myers Squibb acquires Cormorant Pharmaceuticals in deal worth up to $425 million

Bristol-Myers Squibb has announced that it has acquired all outstanding capital stock of Sweden-based Cormorant Pharmaceuticals, granting it access to the company’s HuMax-IL8 antibody program.

Bron: InPharm.com Meer lezen »

Phase III trials for Opdivo show improved overall survival

Bristol-Myers Squibb said late-stage trials for its immuno-therapy Opdivo (nivolumab) showed improved overall survival in lung cancer at the two-year time point. The trials were to evaluate overall survival via two pivotal Phase III studies versus docetaxel in previously treated metastatic non-small cell lung cancer (NSCLC).

Bron: InPharm.com Meer lezen »

Bristol-Myers Squibb’s wonder drug – Opdivo

New data for Bristol-Myers Squibb’s Opdivo to treat head and neck cancer showed superior survival compared with current standard chemotherapies in late stage trials, the company said. The trial was stopped early due to the survival benefit observed with Opdivo, BMS said following recommendations from an independent monitoring committee.

Bron: InPharm.com Meer lezen »

Bristol-Myers Squibb cancer immunotherapy Opdivo approved in EU

Bristol-Myers Squibb has announced that its potentially life-extending cancer immunotherapy, Opdivo (nivolumab), has been approved by the European Commission to treat patients with the most common forms of advanced lung and advanced kidney cancer.

Bron: InPharm.com Meer lezen »

Bristol-Myers Squibb and Pfizer present new analyses of Eliquis (apixaban)

Bristol-Myers Squibb Company and Pfizer Inc. announced that 17 abstracts will be presented at the American College of Cardiology’s 65th Annual Scientific Session, to be held April 2-4 in Chicago, IL.

Bron: World Pharma News Meer lezen »

Bristol-Myers Squibb and Pfizer sign collaboration with Portola Pharmaceuticals

Bristol-Myers Squibb Company and Pfizer Inc. have entered into a collaboration agreement with Portola Pharmaceuticals Inc. to develop and commercialize the investigational agent andexanet alfa in Japan.

Bron: World Pharma News Meer lezen »

EMA fast-tracks BMS multiple myeloma drug

The EMA has recommended granting a marketing authorisation for Bristol Myers-Squibb and AbbVie’s immunotherapy Empliciti for the treatment of multiple myeloma. The drug is to be used in combination with Revlimid (lenalidomide) and the anti-inflammatory medicine dexamethasone for the treatment of patients who have received at least one prior therapy.

Bron: InPharm.com Meer lezen »

GSK to buy HIV drugs from Bristol-Myers Squibb

British pharmaceutical company GlaxoSmithKline said it would buy HIV drugs at different stages of development from U.S. rival Bristol-Myers Squibb in a deal which would boost its ViiV Healthcare unit.

Bron: Reuters Meer lezen »

« Oudere artikelen |